How bad was that original risk-share? Sanofi had to threaten to remove their therapy from the PBS for atopic dermatitis to secure any changes, and it remains so bad that Lilly is not going to list EBGLYSS. …
This could be the canary in the coal mine, but a lot of canaries have already died
June 15, 2025 Latest NewsBioPharmaComment
Latest Video
Georgia Forrest
New Stories
-
US pricing push gets real with Australia included in comparison list
December 22, 2025 - - Latest News -
Parsimony has unfortunately become an enduring test of the institution's legitimacy
December 20, 2025 - - Latest News -
PBAC delivers a broad range of outcomes in November, including for obesity
December 20, 2025 - - Latest News -
Takeda’s next-generation psoriasis therapy delivers landmark Phase 3 results
December 19, 2025 - - Latest News -
A 'fit for purpose' HTA system will be accompanied by a 'fit for purpose' cost recovery framework
December 19, 2025 - - Latest News -
Cleo Diagnostics raises funds to accelerate US launch and advance ovarian cancer screening
December 18, 2025 - - Australian Biotech -
Actinogen crosses key milestone as pivotal Alzheimer’s trial fully enrols
December 18, 2025 - - Australian Biotech